|
16 Nov 2020 |
Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases
|
|
16 Nov 2020 |
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Oph
|
|
16 Nov 2020 |
Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH
|
|
15 Nov 2020 |
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
|
|
15 Nov 2020 |
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
|
15 Nov 2020 |
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
|
|
15 Nov 2020 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
|
|
13 Nov 2020 |
BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations
|
|
13 Nov 2020 |
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
|
|
13 Nov 2020 |
CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
|
|
13 Nov 2020 |
CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza
|
|
13 Nov 2020 |
Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE
|
|
13 Nov 2020 |
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study
|
|
13 Nov 2020 |
Axcella Presents Data for AXA1125 at The Liver Meeting® 2020
|
|
13 Nov 2020 |
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
|
|
13 Nov 2020 |
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience
|
|
13 Nov 2020 |
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
|
|
13 Nov 2020 |
Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions
|
|
13 Nov 2020 |
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
|
13 Nov 2020 |
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
|
